{"id":"W4324136961","doi":"10.1200/jco.2023.41.6_suppl.lba16","title":"Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Internal medicine; Hazard ratio; Abiraterone acetate; Placebo; Progression-free survival; Interim analysis; Oncology; Prednisone; Confidence interval; Androgen deprivation therapy; Cancer; Surgery; Randomized controlled trial; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003115603,0.0002374431,0.001335297,0.0002280257,0.0001052635,0.00004545525,0.0001065201,0.0002123544,0.00008764293],"category_scores_gemma":[0.001022061,0.0001550172,0.0001548716,0.0002260974,0.0003329137,0.0002082857,0.00005610674,0.0007082353,0.00001371877],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002314239,"about_ca_system_score_gemma":0.001875786,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002011788,"about_ca_topic_score_gemma":0.001432395,"domain_scores_codex":[0.9967788,0.0003590921,0.001589481,0.0003576163,0.0004317627,0.000483253],"domain_scores_gemma":[0.9961047,0.00229001,0.000675362,0.0001445037,0.0004004156,0.0003850103],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.652523,0.003703858,0.1049905,0.0008642571,0.002665164,0.004016977,0.001840227,0.0003576384,0.006430954,0.0003140454,0.00620895,0.2160844],"study_design_scores_gemma":[0.3010236,0.09949493,0.5214996,0.0006543318,0.0007494215,0.00020677,0.0007945013,0.001736917,0.001115958,0.002441692,0.06976692,0.0005153877],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9775956,0.002322041,0.00001028849,0.01769069,0.000850433,0.001312316,0.00005865231,0.00001631815,0.0001436528],"genre_scores_gemma":[0.9722468,0.02397693,0.0009688081,0.0003892127,0.0005604217,0.000162333,0.00003330282,0.00004352628,0.001618646],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4165091,"threshold_uncertainty_score":0.6321419,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3104906633709295,"score_gpt":0.5159334548274083,"score_spread":0.2054427914564788,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}